- Laquinimod - submission of application for regulatory approval in the EU planned for second half of 2012
- Phase III data presented at the Annual Meeting of the American Academy of Neurology (AAN) - TASQ - a Phase I investigator-sponsored clinical trial is under way
- enrolment of patients to Phase III study proceeding according to schedule - ANYARA - Phase III trial continuing according to plan
- 57-57 - a clinical trial in systemic sclerosis/scleroderma in progress
- ISI - project is proceeding as planned
- Net sales SEK 2.6 M (2.7)
- Operating loss SEK 100.7 M (loss: 70.9)
- Net loss SEK 99.0 M (loss: 69.3 )
- Loss per share for the period was SEK 1.44 (loss: 1.02)
For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam
CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB (Corp Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
This report is also available at www.activebiotech.com
